US 11,746,150 B2
Anti-LRP5/6 antibodies and methods of use
Yang Li, Mountain View, CA (US); Tom Zhiye Yuan, Union City, CA (US); Aaron Ken Sato, Burlingame, CA (US); Wen-Chen Yeh, Belmont, CA (US); and Parthasarathy Sampathkumar, South San Francisco, CA (US)
Assigned to Surrozen Operating, Inc., South San Francisco, CA (US)
Appl. No. 16/954,483
Filed by Surrozen Operating, Inc., South San Francisco, CA (US)
PCT Filed Dec. 19, 2018, PCT No. PCT/US2018/066620
§ 371(c)(1), (2) Date Jun. 16, 2020,
PCT Pub. No. WO2019/126401, PCT Pub. Date Jun. 27, 2019.
Claims priority of provisional application 62/680,515, filed on Jun. 4, 2018.
Claims priority of provisional application 62/607,879, filed on Dec. 19, 2017.
Prior Publication US 2021/0079089 A1, Mar. 18, 2021
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/28 (2013.01) [C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01)] 10 Claims
 
1. An isolated antibody, or an antigen-binding fragment thereof, that binds to one or more LRP5 or LRP6 receptor, comprising a sequence comprising:
a CDRH1 sequence of SEQ ID NO:107, a CDRH2 sequence of SEQ ID NO:203 and a CDRH3 sequence of SEQ ID NO:452 or any one of SEQ ID NOs: 609-618.